Skip to Content

Phenyltoloxamine

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0000092-12-6

Chemical Formula

C17-H21-N-O

Molecular Weight

255

Therapeutic Categories

Antiallergic agent

Histamine H₁-receptor antagonist (H₁-antihistaminic)

Chemical Name

Etanamine, N,N-dimetyl-2-[2-(phenylmetyl)phenoxy]-

Foreign Names

Generic Names

Brand Names

  • Codipront [+ Codeine]
    Asmeco, Thailand; CTS Chemical, Hong Kong; Ferraz, Malta; Ferraz, Portugal; Grünenthal, Peru; Heinrich, Kuwait; Kimia Farma, Indonesia; October Pharma, Egypt; RX Pharma, Singapore; Zuoz, Venezuela
  • Codipront Expectorante [+ Codeine, + Guaifenesin]
    Grünenthal, Peru
  • Codivis [+ Codeine]
    CTS, Israel
  • Lentusin [+ Dihydrocodeine]
    S.Chobet, Argentina
  • Pholtex [+ Pholcodine]
    iNova, South Africa
  • Sinutab [+ Paracetamol, + Phenylpropanolamine]
    Hikma, Egypt
  • Tussionex [+ Dihydrocodeine]
    Teva, Uruguay
  • Tussionex [+ Hydrocodone]
    Sanofi-Aventis, Canada
  • Biocidan [+ Cethexonium]
    Menarini, France
  • Codipront [+ Codeine]
    Heinrich Mack, Lithuania

Glossary

TermDefinition
BANBritish Approved Name
BANMBritish Approved Name (Modified)
DCFDénomination Commune Française
DCITDenominazione Comune Italiana
ISInofficial Synonym
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide